




Amifampridine

Revised: June 3, 2019.

CASRN: 54-96-6



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of amifampridine during breastfeeding on the presence of amifampridine or the 3-N-acetyl-amifampridine metabolite in breastmilk. If amifampridine is required by the mother, it is not a reason to discontinue breastfeeding, but the infant should be carefully monitored for excessive crying or fussiness, adequate weight gain, and developmental milestones.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Amifampridine

CAS Registry Number

54-96-6

Drug Class

Breastfeeding

Lactation

Neuromuscular Agents

Potassium Channel Blockers